In addition, experiments in bladder cancer cells harboring FGFR3 fusions and activating PI3K/Akt mutations should also be conducted to explore the efficacy of SIP-SII in combination with FGFR inhibitors under more restrictive mutational landscapes. This evidence concerns the gene FGFR3 and urinary bladder carcinoma.